SEC Form 4 · accession 0001209191-16-092049
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David R Walt
Director
Period of report
Jan 14, 2016
Accepted (ET)
Jan 19, 2016 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 14, 2016 | P | 4,400 | $2.6427 | A | 67,031 | D | |
| Common StockF3 | Jan 15, 2016 | P | 4,172 | $2.4169 | A | 71,203 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These purchases were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2015.
- F2Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.60 to $2.70 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
- F3Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.33 to $2.51 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.